Q-omics provides the consensus-scored FBXO36 profile across patient tissues and cancer cell-line models. FBXO36 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, FBXO36 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, FBXO36 RNA expression shows 20,500 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KICH, and UVM as cancer lineages where FBXO36 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO36 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO36 survival associations across molecular data types. FBXO36 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO36 RNA expression–survival associations across cancer types. High FBXO36 expression shows favorable associations in BRCA, KIRC, UCEC, COAD, PRAD and MESO. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for FBXO36 RNA expression.
This table summarizes FBXO36 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FBXO36. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO36 shows lower tumor expression in KICH, THCA, KIRC and LUSC and higher tumor expression in LIHC and STAD. The KICH box plot shows higher FBXO36 RNA expression in normal versus tumor tissue (log2 FC = −1.920, t-test p < 0.001).
This table shows molecular features associated with FBXO36 in patient tissues and cancer cell lines. In patient samples, FBXO36 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO36 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
